ArticlemBio2021
ApmA Is a Unique Aminoglycoside Antibiotic Acetyltransferase That Inactivates Apramycin.
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Carbapenem and colistin-resistantJAC-antimicrobial resistance · 2026Article
- Genes and physiological strategies in bacterial antibiotic resistance.Frontiers in microbiology · 2026Review
- Design, Synthesis, and Biological Evaluation of 6″-Modified Apramycin Derivatives to Overcome Aminoglycoside Resistance.Pharmaceutics · 2025Article
- An Overview of the Epidemiology of Multidrug Resistance and Bacterial Resistance Mechanisms: What Solutions Are Available? A Comprehensive Review.Microorganisms · 2025Review
- The global resistance problem and the clinical antibacterial pipeline.Nature reviews. Microbiology · 2025Review
- Global dissemination of npmA mediated pan-aminoglycoside resistance via a mobile genetic element in Gram-positive bacteria.Nature communications · 2025Article
- Distinct Patterns of Antibiotic Sensitivities in Ammonia-Oxidising Archaea.Environmental microbiology · 2025Article
- Beyond antibiotics: exploring multifaceted approaches to combat bacterial resistance in the modern era: a comprehensive review.Frontiers in cellular and infection microbiology · 2025Review
- Exogenous NADH promotes the bactericidal effect of aminoglycoside antibiotics againstVirulence · 2024Article
- Mechanistic plasticity in ApmA enables aminoglycoside promiscuity for resistance.Nature chemical biology · 2024Article
- Resistance against aminoglycoside antibiotics via drug or target modification enables community-wide antiphage defense.microLife · 2024Article
- Antibiotic persistence and its impact on the environment.3 Biotech · 2023Review
- The Combination of Antibiotic and Non-Antibiotic Compounds Improves Antibiotic Efficacy against Multidrug-Resistant Bacteria.International journal of molecular sciences · 2023Review
- Biosynthetic Origin of the Octose Core and Its Mechanism of Assembly during Apramycin Biosynthesis.Journal of the American Chemical Society · 2023Article
- Potential of Natural Phenolic Compounds as Antimicrobial Agents against Multidrug-ResistantMolecules (Basel, Switzerland) · 2023Article
- Molecular mechanisms of antibiotic resistance revisited.Nature reviews. Microbiology · 2023Review
- InvasiveFrontiers in cellular and infection microbiology · 2023Article
- Discovery and development of inhibitors of acetyltransferase Eis to combat Mycobacterium tuberculosis.Methods in enzymology · 2023Article
- Apramycin resistance in epidemic carbapenem-resistant Klebsiella pneumoniae ST258 strains.The Journal of antimicrobial chemotherapy · 2021Article
- Potential for the Development of a New Generation of Aminoglycoside Antibiotics.Pharmaceutical chemistry journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Apramycin is an aminoglycoside antibiotic with the potential to be developed to combat multidrug-resistant pathogens. Its unique structure evades the clinically widespread mechanisms of aminoglycoside resistance that currently compromise the efficacy of other members in this drug class. Of the aminoglycoside-modifying enzymes that chemically alter these antibiotics, only AAC(3)-IVa has been demonstrated to confer resistance to apramycin through
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.